Evidence map›Paper›PMID 38493006›Full record

ReviewBlood reviews2024

Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?

Geoffrey L Uy, Daniel J DeAngelo, Jay N Lozier, Dennis M Fisher, Brian A Jonas, John L Magnani, Pamela S Becker, Hillard M Lazarus, Ingrid G Winkler

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Blood reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 2 countries.

Geoffrey L UyDivision of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Daniel J DeAngeloDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jay N LozierGlycoMimetics, Inc., Rockville, MD, USA. Electronic address: jlozier@glycomimetics.com.
Dennis M FisherP Less Than, San Francisco, CA, USA.
Brian A JonasDepartment of Internal Medicine, Division of Malignant Hematology/Cellular Therapy and Transplantation, University of California Davis, Davis, CA, USA.
John L MagnaniGlycotech, Inc., Rockville, MD, USA.
Pamela S BeckerLeukemia Division, Department of Hematology and Hematopoietic Cell Transplantation, Department of Hematologic Malignancies Translational Science, City of Hope National Medical Center, Duarte, CA, USA.
Hillard M LazarusDepartment of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Ingrid G WinklerMater Research Institute - The University of Queensland, Translational Research Institute, Brisbane, Woolloongabba, QLD, Australia.
Case Western Reserve University · USCity Of Hope National Medical Center · USDana-Farber Cancer Institute · USGlycoMimetics (United States) · USUniversity of California, Davis · USUniversity of Queensland · AUWashington University in St. Louis · US

Funding

Clinician Scientist in LeukemiaR50CA275927 · NCI · WASHINGTON UNIVERSITY · PI GEOFFREY L UY · 2023 to 2026
$531k
NCI R50 Clinician Scientist AwardR50CA276013 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Brian A. Jonas · 2023 to 2026
$349k
NCI NIH HHS R50 CA275927NCI NIH HHS R50 CA276013
6 · The paper itself

Abstract

E-selectin, a cytoadhesive glycoprotein, is expressed on venular endothelial cells and mediates leukocyte localization to inflamed endothelium, the first step in inflammatory cell extravasation into tissue. Constitutive marrow endothelial E-selectin expression also supports bone marrow hematopoiesis via NF-κB-mediated signaling. Correspondingly, E-selectin interaction with E-selectin ligand (sialyl Lewis

Indexed as

Hematologic NeoplasmsLeukemia, Myeloid, AcuteBone MarrowEndothelial CellsE-SelectinHumansE-SelectinAcute myeloid leukemia (AML)E-selectinHematologic malignanciesSelectinUproleselan

Identifiers

PMID38493006
PMCPMC11051645
OpenAlexW4392247543

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.